Foster Victor Wealth Advisors LLC Purchases New Position in Medtronic PLC $MDT

Key Points

• Foster Victor Wealth Advisors purchased a new stake of 96,393 shares in Medtronic in Q4 (≈$9.33M), as other institutions also added to positions, bringing institutional ownership to 82.06%.
• Medtronic beat quarterly expectations with $1.36 EPS and $9.02B revenue, set FY2026 guidance of $5.62–$5.66 EPS, and declared a quarterly dividend of $0.71 (3.2% yield; ex-dividend March 27).
• EVP Harry Skip Kiil sold 52,524 shares on Feb 19 for about $5.13M, cutting his ownership by ~61.6% and leaving insiders with only 0.26% of the stock.

Foster Victor Wealth Advisors LLC purchased a new stake in Medtronic PLC (NYSE:MDT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 96,393 shares of the medical technology company's stock, valued at approximately $9,327,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Barclays PLC boosted its holdings in Medtronic by 104.6% in the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company's stock valued at $650,604,000 after purchasing an additional 3,492,192 shares in the last quarter. Schroder Investment Management Group boosted its holdings in Medtronic by 78.3% in the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company's stock valued at $717,143,000 after purchasing an additional 3,307,211 shares in the last quarter. Guinness Asset Management LTD acquired a new position in Medtronic in the third quarter valued at approximately $275,556,000. Wellington Management Group LLP boosted its holdings in Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock valued at $970,456,000 after purchasing an additional 2,658,981 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Medtronic by 2,297.7% in the fourth quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company's stock valued at $241,179,000 after purchasing an additional 2,406,000 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is owned by company insiders.

Medtronic Price Performance

Shares of NYSE MDT opened at $88.11 on Wednesday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.93 and a twelve month high of $106.33. The stock has a 50 day moving average of $92.48 and a two-hundred day moving average of $95.89. The stock has a market cap of $113.12 billion, a P/E ratio of 24.54, a P/E/G ratio of 2.28 and a beta of 0.75.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, March 27th. Medtronic's dividend payout ratio is 79.11%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Truist Financial lowered their price target on Medtronic from $107.00 to $103.00 and set a "hold" rating for the company in a report on Wednesday, February 18th. Daiwa Securities Group lowered their price target on Medtronic from $117.00 to $115.00 and set a "buy" rating for the company in a report on Friday, February 27th. William Blair raised Medtronic from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 6th. Robert W. Baird reduced their price objective on Medtronic from $103.00 to $100.00 and set a "neutral" rating for the company in a research note on Wednesday, February 18th. Finally, UBS Group reiterated a "neutral" rating and issued a $104.00 price objective on shares of Medtronic in a research note on Wednesday, February 4th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $110.00.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.